Sensei Biotherapeutics Q2 net loss $7.1M; cash $52.3M; SNS-101 dose expansion on track

Sensei Biotherapeutics, Inc.

2024-Q2 EPS reported -$0.60

Net loss $7.1M vs $9.4M in Q2 2023; R&D $4.6M (-$0.2M), G&A $3.2M (-$2.2M).
Cash $52.3M, expected to fund operations into Q4 2025.
Phase 1/2 SNS-101 dose expansion enrollment advancing; initial data Q4 2024; end-of-Phase 1 FDA meeting by year-end.
ASCO 2024 data showed well-tolerated safety, best-in-class PK, and early clinical activity.
Appointed Josiah Craver as SVP of Finance, effective July 22, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.